FOREWORD OF THE EDITOR

Dr. Bruce W. M. Jordan, Ph.D., FIBMS was trained in laboratory medicine, graduating from the University of Portsmouth U.K. in 1994 with a BSc. (Hons.) Biomedical Sciences, subsequently achieving state registration in hematology and transfusion medicine at Southampton General Hospital in 1995. He has also worked at the Royal Marsden Hospital, London, and has a Ph.D. in cancer research from the University of Würzburg in Germany.

Dr. Jordan joined the Roche Pharmaceuticals Herceptin® Team in Basel, Switzerland in 2005, leading the HER2 Testing/Companion Diagnostics (CDx) activities, and has since worked in developing CDx in many different therapeutic areas, including asthma, Alzheimer’s disease, cardiovascular diseases and oncology. Since January 2013 he is International Business Leader - CDx, in Roche Professional Diagnostics HQ in Rotkreuz, Switzerland.

Dr. Jordan also represents the diagnostics industry as a corporate representative at the IFCC Communications and Publications Division (CPD) Executive Committee, member of the European Society of Pharmacogenetics and Theranostics (ESPT), and is a fellow of the Institute of Biomedical Sciences (FIBMS) in the U.K.

Gabor L. Kovacs MD, PhD, DSc.
eJournal IFCC Editor-in-chief